MHC class II genotypes are independent predictors of anti-PD1 immunotherapy response in melanoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
MHC class II genotypes are independent predictors of anti-PD1 immunotherapy response in melanoma ; volume:4 ; number:1 ; day:30 ; month:9 ; year:2024 ; pages:1-8 ; date:12.2024
Communications medicine ; 4, Heft 1 (30.9.2024), 1-8, 12.2024
- Creator
-
Claeys, Arne
Van den Eynden, Jimmy
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s43856-024-00612-w
- URN
-
urn:nbn:de:101:1-2412152113415.511588358555
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Claeys, Arne
- Van den Eynden, Jimmy
- SpringerLink (Online service)
Other Objects (12)
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
Immunotherapy of malignant melanoma
Phenotypes and Genotypes of Melanoma Patients
Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma
Minimal change disease associated with anti-PD1 immunotherapy: a case report
Development of MHC-dependent immunotherapy for gliomas
Computational immunology : from MHC-peptide binding to immunotherapy
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Beyond PD-1 Immunotherapy in Malignant Melanoma
Advances in predictive biomarkers for melanoma immunotherapy
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
Immunotherapy of malignant melanoma
Phenotypes and Genotypes of Melanoma Patients
Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma
Minimal change disease associated with anti-PD1 immunotherapy: a case report
Development of MHC-dependent immunotherapy for gliomas
Computational immunology : from MHC-peptide binding to immunotherapy
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Beyond PD-1 Immunotherapy in Malignant Melanoma
Advances in predictive biomarkers for melanoma immunotherapy
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
Immunotherapy of malignant melanoma
Phenotypes and Genotypes of Melanoma Patients
Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma
Minimal change disease associated with anti-PD1 immunotherapy: a case report
Development of MHC-dependent immunotherapy for gliomas
Computational immunology : from MHC-peptide binding to immunotherapy
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
Beyond PD-1 Immunotherapy in Malignant Melanoma